Athira Pharma (NASDAQ:ATHA) Stock Price Up 0.6% – Still a Buy?

Athira Pharma, Inc. (NASDAQ:ATHA)’s share price was up 0.6% during mid-day trading on Monday . The stock traded as high as $5.06 and last traded at $4.74. Approximately 50,082 shares changed hands during trading, a decline of 98% from the average daily volume of 3,210,973 shares. The stock had previously closed at $4.71.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Athira Pharma has a consensus rating of “Sell” and a consensus price target of $4.00.

Athira Pharma Price Performance

The stock has a market cap of $18.69 million, a P/E ratio of -0.49 and a beta of 2.79. The firm’s fifty day moving average price is $5.74 and its two-hundred day moving average price is $4.65.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). On average, research analysts expect that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Athira Pharma

An institutional investor recently bought a new position in Athira Pharma stock. Focus Partners Wealth bought a new position in Athira Pharma, Inc. (NASDAQ:ATHA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned approximately 0.21% of Athira Pharma as of its most recent filing with the Securities & Exchange Commission. 57.12% of the stock is currently owned by institutional investors and hedge funds.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.